Member Info for smudge99

https://www.business-live.co.uk/enterprise/home-testing-healthcare-firm-myhealthchecked-22824124

In lieu of the update it looks like mhc are targeting UK travellers from Manchester to the usa with their pcr offering. Hadn't spotted this before so good to know things continue to happen behind the scenes!
https://myhealthchecked.com/covid-19-travel-test-guide-for-the-usa

Is the mdna supplier the same one as quoted on the ygen website for using clarigene?
https://www.yourgene-health.com/covid-19-day-2-and-day-8-testing-service-providers

In addition to Mr fox it looks like few more other people have visited the website in December:
https://www.similarweb.com/website/myhealthchecked.com/
100% increease seems good to me. Not sure how mhc are marketing their own brand but something seems to be working.

Good to see the improved comms from the company promoting their achievements. Out of of all the suppliers that could supply the flowflex lft they choose MHC - I think this speaks volumes about how MHC are regarded by Lloyds. Also interesting to see Boots offer a similar antigen service but with the added promotion of use for events. I can't find any reference to who offers this service but maybe in the future MHC could be considered by Boots to get involved if they have the bandwidth. The good thing with the MHC business model is that they have many options. Should be an interesting 2022!

I understand that boots use sbi and mhc for their at home testing pcr offering. Both these companies offer lft verification services. I see that boots offer lft service that require a negative certificate:
https://www.boots.com/services/covid-19-testing/pre-departure-to-uk-covid-19-travel-testing
Does anyone know who boots use for this and is it something that mhc could be used for? I can't find info that suggests who supplies this so maybe it's a boots interal supply offering. Any clarification would be welcome.

In addition to the seal advisors research note I noticed this the other day that the following link gives a potential value to the thriva business that was compared to in the testing offering comparison info with mhc.
https://pembrokevct.com/?portfolio=thriva
Not sure when the valuation was completed but it seems to indicate that the 7% ownership was worth 11 million. If the intpretation is correct then this is being valued as +100m market cap for their test portfolio. Happy to be corrected if the data suggests something else.

Great update today and with the cash available has good options. I like the company description used in their recent quality manager job ad:
About the company:

Concepta is an at-home test provider with specialisms in technical development and a UK retail and direct-to-consumer customer base, and with an ISO 15189 accredited testing laboratory in Manchester.
It has its own ip tests(pending release in 2020), own lab (with sequencing capability I believe), can sell third party tests and has retail and consumer direct links. The foundations are being laid, its a great story. Can they sell their tests? I would think so. The first half of next year is going to be interesting to see where this one goes!

A link copied from the abdx bb
https://clpmag.com/diagnostic-technologies/clinical-laboratories-16-industry-predictions-for-2022/
Hopefully a company selling at home testing, whatever test that may be, will do well in 2022

Interesting post regarding letsgetchecked comparison. I believe everlywell is another US company that supplies into wallgreens with a not unfamilar product lineup which provides another comparison. None of these show on the seal advisors breifing note on MHC though but they do include a company called dnafit owned by prenetics. Prenetics also own the covid tests sold through projectscreeen. These website based portals had about 1.7m (covid) and 60K (dna) vistors last month. MHC vistor numbers 100k, Boots recova testing portal 1.6m , lloyds pcr vistors ?. Not bad bad for a company of 18 employees. If they get the dna products into the high street websites offering then its got to generate more revenue than the DNA fit coverage, surely? The seal advisor breifing note quotes the following for a forthcoming IPO: 'Prenetics(Hong Kong based looking to list in the US), London Medical Laboratory (UK based clinical testing). No valuation though but the following link provides one:
https://www.reuters.com/article/prenetics-ipo-idUSKBN2GC03N
I think prenetics has employees in their hundreds and operate abroad though so a valuation like this could be someway off for MHC but hopefully the market cap will increase just a bit at the next update! GLA

And lloyds pharmacy are back up with the mhc day 2 and day8 pcr tests too!

Looks like the Fit2fly rapid antigen test is up and running
https://myhealthchecked.com/product/fit-to-fly-rapid-antigen-test

I agree definitely a good spot spot by smtrading on the lft. And good to see they've reintroduced the Christmas hours chart on their website that it was spotted on, investors influencing the BOD! I listened back the investors q and a on the lft and I think PM was being canny on the answer in that they have no intention to develop one, avoided the bit about selling one! Definitely happy to see how the next few months play out.

Not sure if this has been posted before but quite an interesting listen:

https://soundcloud.com/user-88146587/211005-myhealthchecked-final/s-VwoTZINZHCR?si=b430d7556be84cbfbc9a1f4b7d5a1252

Looks like mhc are now selling the pcr arrival tests through lloyds:
https://lloydspharmacy.com/search?q=myhealthchecked

The suggestion from the mhc seal advisors info is that covid testing will peak in 2023. Presumably that's all types of testing and pcr is a chunk of that. It's good to see mhc tweaking their prices through the covid testing website portal to remain competitive for the pcr offering, £54 for f2f.
https://www.covid19-testing.org/providers
Hopefully this will increase traffic and purchasers to their own website. Also, anyone else notice the rate of increase in trust pilot reviews there have been in the last few weeks. Be interesting to see if they can gain pcr market share during this period. If they can it might give confidence in their marketing capability. Hopefully they'll be an indicator in October's similarweb website stats.Share price down but the business is definitely not out. Imo. DYOR and lastly GLA

Investor relations might be a good place to start.

I think the bet on this one is whether they can achieve what prenetics (Hong Kong registered company) are on the verge on achieving. The mhc oberon seal advisors doc quotes it as uk based testing. They bought dnafit and massively expanded during covid through the project screen and airline tie up and looking to list on the nasdaq to expand worldwide. There are a few valuations around but it goes to show what could be achieved via UK based testing. Prove the model out and expand. It looks like 2022 will be when we find out what the mhc dna offering will be like. I thought the thriva offering looks good but no idea if mhc will go along these lines. GLA.
https://www.cityam.com/hong-kong-covid-19-testing-firm-prenetics-set-to-float-in-us-with-spac-deal/

I've just listened to the presentation again and it does seem unlikely to go down the lft route. I guess if this did help the long term business plan then it might be possible but I struggle to see how it fits in when the mylotus lft has been confirmed to be parked for the time being. I'm hoping they concentrate on the tests with their IP now. They've proved they can make a profit selling a third party test, so bodes well for the post wellness test phase and selling all manner of pcr tests to the at home market. Like most people now just curious how well the nell platform tech is received. 2022 should be interesting!

I agree with the comments, defo concentrating on the business not the shareholder, which if they did would probably go into the ramping territory. I quite liked the focus. A couple of things peeked my interest apart from the new test panels: the covert description of the app offering in q2 - hopefully this is a tech consumer health leap and the possible tweak to the covid offering highlighted on the time line slide. Not sure what is meant by this. Whereever this company goes its quite a feat to get to the place they are from their concepta days - sounds like they needed more investment to realise the fertility tech. GLA